Scientist

Manager / Senior Manager, Translational Science (Cardiology & Cell Therapy)

Dallas, Texas, United States (Remote)

Hartmann Young are partnering with a fast‑growing, privately held biotech advancing a novel cell‑based therapeutic platform for cardiovascular disease, with a primary focus on cardiomyopathy and heart failure. The company operates as a lean, highly scientific organization, offering individuals significant ownership across translational and early clinical development.

This is a high‑impact Manager / Senior Manager‑level role for a translational biologist who brings deep in vivo expertise, strong study‑design capability, and the adaptability to work across indications in an evolving pipeline. The role is remote across the U.S., with Dallas / Plano–based candidates strongly preferred given the company’s growing presence in Texas and future laboratory plans.This is an urgent hire at a critical development inflection point.

The Role

You will play a central role in shaping and executing the company’s translational strategy, bridging mechanistic biology, nonclinical modeling, and early clinical development. While cardiology experience is highly desirable, the role is intentionally broad and suited to someone with a cell therapy background beyond oncology, such as autoimmune, regenerative medicine, or adjacent therapeutic areas.

This position requires someone who has personally designed and executed in vivo studies and can now apply that experience strategically in a leadership role.

Key Responsibilities

• Provide scientific leadership across translational biology activities supporting programs from preclinical through early clinical development (Phase 1/2)
• Design, oversee, and interpret in vivo and in vitro studies, including nonclinical efficacy, mechanistic, and PK/PD work
• Serve as a subject‑matter expert in animal models relevant to cardiomyopathy, heart failure, and related non‑oncology indications
• Translate preclinical findings into:
• Clinical hypotheses
• Biomarker and translational strategies
• Dose and regimen rationale
• Support IND‑enabling activities, including contribution to translational sections of regulatory submissions
• Author and review key program documents such as:
• Nonclinical study reports
• Investigator’s Brochures
• Translational components of protocols
• Manage and collaborate with CROs, academic partners, and external vendors, including oversight of timelines and data quality
• Partner cross‑functionally with Clinical Development, Regulatory, Biometrics, and Operations
• Support interpretation of emerging clinical data in the context of preclinical and translational evidence
• Operate effectively in a resource‑lean, high‑ownership biotech environment

Expertise We’re Looking For

Required:

• Extensive hands‑on in vivo experience gained through graduate training and/or industry
• Candidates must have personally designed and executed animal studies, even if day‑to‑day bench work is no longer central to their role
• Strong background in translational biology, including study design, execution, and interpretation
• Experience managing or partnering with external CROs
• Comfortable working across multiple scientific approaches and indications
• High scientific rigor, adaptability, and intellectual curiosity

Strongly Preferred:

• Experience in cardiology (e.g., cardiomyopathy, heart failure), or adjacent non‑oncology therapeutic areas (e.g., neuro, autoimmune)
• Cell therapy experience outside of oncology (e.g., autoimmune, regenerative medicine, stem‑cell–based platforms)
• Familiarity with non‑tumor models, as this will not be an oncology‑focused company
• Exposure to IND‑related or IND‑enabling research
• Experience in small biotech or early clinical development environments

Education:

• PhD preferred, but a Master’s degree with extensive, relevant translational and in vivo experience will be considered

Personal Profile:

• High‑quality performer with a strong work ethic and ownership mindset
• Adaptable, eager, and comfortable operating in ambiguity
• Able to clearly discuss multiple indications and scientific philosophies
• Does not need to be highly “validated,” but must be confident and credible across translational disciplines
• Comfortable with the pace and breadth of responsibility typical of an early‑stage biotech

Why Join?

• Join a mission‑driven biotech addressing high‑unmet‑need cardiovascular diseases
• Significant hands‑on scientific ownership with real influence on program direction
• Exposure to a dynamic, cell‑therapy platform with relevance beyond a single indication
• Flat organizational structure with high visibility
• Remote U.S. role, with added opportunity for impact if Dallas‑based